Exbivirumab Biosimilar - Research Grade

Human

HBV

>1mg/ml

IgG1 - lambda2

CHO Cells

Lenvervimab Biosimilar - Research Grade (ICH5632), Libevitug Biosimilar - Research Grade (ICH5641), Libivirumab Biosimilar - Research Grade (ICH5642), Tobevibart Biosimilar - Research Grade (ICH5931), Tuvirumab Biosimilar - Research Grade (ICH5950)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of exbivirumab, a fully human IgG1 (lambda light chain) monoclonal antibody directed against the hepatitis B virus (HBV) surface antigen (HBsAg). The originator was investigated as a passive immunoprophylaxis agent to bind and neutralize circulating HBV, for example in the setting of preventing graft reinfection after liver transplantation. This research-grade version reproduces the antigen-binding specificity of the originator but is supplied for research use only (RUO); it is not the clinical drug and is not intended for human or veterinary use. Because it carries a native, unconjugated human IgG1 backbone with defined anti-HBsAg specificity, it is useful as a positive control and reference reagent for assays that involve HBsAg detection, virus neutralization, or Fc-dependent effector characterization, and as a starting point for conjugate or assay development. It is offered as a low-endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) preparation available in bulk milligram-to-gram quantities to support in-vitro workflows and preclinical standardization. Hepatitis B virus (HBV) is a small enveloped DNA virus (family Hepadnaviridae) that causes acute and chronic liver infection. Its envelope carries the hepatitis B surface antigen (HBsAg), expressed as large, middle, and small forms and secreted in vast excess as non-infectious subviral particles alongside intact virions. HBsAg is the principal neutralizing target: the immunodominant "a" determinant within the S domain is the epitope recognized by protective anti-HBs antibodies and by hepatitis B immune globulin. Antibodies binding this region can block virion attachment and entry into hepatocytes (mediated in part by the NTCP receptor) and can flag HBsAg-bearing particles for clearance. HBsAg is also the clinical marker of infection and the basis of the HBV vaccine, making anti-HBsAg reagents central to HBV serology, neutralization, and vaccine-related research.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Exbivirumab biosimilar available in bulk or gram quantities?

A: Yes — the Exbivirumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Exbivirumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Exbivirumab biosimilar bind?

A: It is an unconjugated, non-therapeutic analog of Exbivirumab that recognises HBV.